Optimi Health Exports Psilocybin to Australia
Analysis based on 12 articles · First reported Jun 29, 2026 · Last updated Jun 29, 2026
The successful export by Optimi Health to Australia demonstrates the growing commercial viability and regulatory acceptance of psychedelic medicines for mental health treatments. This could lead to increased investor confidence in Optimi Health and the broader psychedelic pharmaceutical industry, potentially driving stock prices higher for companies in this emerging sector.
Optimi Health, a Canadian pharmaceutical manufacturer, has completed its third commercial export of 1,000 capsules of 5mg psilocybin to Australia. These capsules are prescribed in Australia for treatment-resistant depression, an indication for which regulated patient access is available. Australia became the first country to recognize psilocybin as a medicine in July 2023, and Optimi Health is one of the few Nasdaq-listed companies commercially supplying psilocybin outside of clinical trials. The company's CEO, Dane Stevens, highlighted Australia as a model for safe psilocybin prescription, noting no serious adverse events reported. The products are manufactured in Optimi Health's GMP facility in Canada under Canada — Health Canada's license and are reimbursed by various public and private payers in Australia.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard